Work

Genetics and immunology: reinvigorated

Year: 2015

Type: article

Abstract: Immune checkpoint blockade therapy is changing oncology by improving the outcome of patients with advanced malignancies. Our research has revealed the genetic features of tumors present in patients who initiate a successful antitumor immune response and derive clinical benefit from immune checkpoint blockade therapy versus non-responders.

Source: OncoImmunology

DOI: 10.1080/2162402x.2015.1029705

Authors: Alexandra Snyder, Vladimir Makarov, Matthew Hellmann, Naiyer Rizvi, Taha Merghoub, Jedd D Wolchok, Timothy A Chan

Institutions: Memorial Sloan Kettering Cancer Center, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W1878765122

FWCI: 0.728

Cites: 8

Cited by: 7

Related to: 10